Filing Details
- Accession Number:
- 0001437749-14-011463
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-06-18 17:46:11
- Reporting Period:
- 2014-06-16
- Filing Date:
- 2014-06-18
- Accepted Time:
- 2014-06-18 16:46:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1484478 | Furiex Pharmaceuticals Inc. | FURX | Pharmaceutical Preparations (2834) | 271197863 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1492646 | Frances Gail Mcintyre | C/O Furiex Pharmaceuticals, Inc., 3900 Paramount Parkway, Suite 150 Morrisville NC 27560 | Senior Vice President-Research | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-06-16 | 3,804 | $105.00 | 24,318 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2014-06-16 | 32,928 | $9.11 | 57,246 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-06-16 | 32,928 | $105.00 | 24,318 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2014-06-16 | 26,000 | $15.00 | 50,318 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-06-16 | 26,000 | $105.01 | 24,318 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2014-06-16 | 3,717 | $13.16 | 28,035 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-06-16 | 3,717 | $105.05 | 24,318 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2014-06-17 | 8,008 | $13.16 | 32,326 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-06-17 | 8,008 | $105.00 | 24,318 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (to buy) | Disposition | 2014-06-16 | 32,928 | $0.00 | 32,928 | $9.11 |
| Common Stock | Stock Options (to buy) | Disposition | 2014-06-16 | 26,000 | $0.00 | 26,000 | $15.00 |
| Common Stock | Stock Options (to buy) | Disposition | 2014-06-16 | 3,717 | $0.00 | 3,717 | $13.16 |
| Common Stock | Stock Options (to buy) | Disposition | 2014-06-17 | 8,008 | $0.00 | 8,008 | $13.16 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 22,763 | 2020-06-17 | No | 4 | M | Direct | |
| 0 | 2021-05-09 | No | 4 | M | Direct | |
| 34,227 | 2021-10-03 | No | 4 | M | Direct | |
| 26,219 | 2021-10-03 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (to buy) | $17.80 | 2022-02-24 | 10,368 | 10,368 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2022-02-24 | 10,368 | 10,368 | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.03, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.03 to $105.08, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- All options became 100% vested on June 11, 2014 in connection with the Agreement and Plan of Merger dated as of April 27, 2014 by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc.
Billionaire Hedge Funds
